Skip to content

Role of Homoeopathy in Bronchial Asthma

Effectiveness of Individualised Homoeopathic Medicines Selected Using Allens Encyclopedia of Pure Materia Medica in the Management of Bronchial Asthma: A Prospective, Open-Label, Single-Arm Clinical Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094312
Enrollment
40
Registered
2025-09-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: individualised homoeopathic medicine: Participants will receive individualised homoeopathic medicines, selected based on homoeopathic principles, using Allen?s Encyclopedia of Pure Mat

Sponsors

Nehru Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients presenting with clinical signs & symptoms consistent with bronchial asthma, after confirming the diagnosis with Lung Function Tests (spirometry). 2. Patients with a confirmed diagnosis of bronchial asthma by a qualified medical practitioner (based on clinical history and/or diagnostic tests). 3. Patients aged between 17 to 70 years irrespective of their gender. 4. Patients on conventional treatment for bronchial asthma. 5. Patients who are willing to participate and provide written informed consent.

Exclusion criteria

Exclusion criteria: Participants meeting any of the following criteria will be excluded from the study: 1. Patients diagnosed with severe persistent asthma with significant restriction of daily activities. 2. Patients experiencing status asthmaticus. 3. Patients with serious complications or uncontrolled/life-threatening systemic illnesses (e.g., cardiac failure, uncontrolled diabetes, renal or hepatic failure). 4. Patients diagnosed with any psychiatric illness that may interfere with compliance or assessment. 5. Pregnant women and lactating mothers. 6. Individuals with a history of substance abuse or dependence. 7. Patients unwilling or unable to provide informed consent or participate in the study procedures. 8. Individuals with a self-reported immunocompromised state (e.g., HIV, ongoing immunosuppressive therapy).

Design outcomes

Primary

MeasureTime frame
proportion of patients showing a clinically significant improvement in ACT scoresTimepoint: ACT will be estimated at baseline & at every 4 week interval. Final assessment will be done after 6 months of enrolment.

Secondary

MeasureTime frame
improvement in quality of life using AQLQ(S) & documentation of the spectrum of prescribed medicinesTimepoint: AQLQ(S) scores will be estimated at baseline & at every 4 weeks. Final assessment will be done after 6 months of enrolment.

Countries

India

Contacts

Public ContactDr George Mathew

Nehru Homoeopathic Medical College and Hospital

drgeorgem@gmail.com7982783132

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026